Understand the source comparison
Follistatin-344 FAQ: Research Applications Comparison
Follistatin-344 research spans muscle hypertrophy, metabolic disease, fibrosis, and reproductive biology. The table below compares primary research applications, typical experimental models, dosing ranges reported in peer-reviewed literature, and key outcome m
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Follistatin-344 research spans muscle hypertrophy, metabolic disease, fibrosis, and reproductive biology. The table below compares primary research applications, typical experimental models, dosing ranges reported in peer-reviewed literature, and key outcome measures that define study endpoints.
- Skeletal muscle hypertrophy
- Murine IM injection, AAV gene therapy
- 10–100 µg per injection site; AAV 1×10^11 genome copies
- Muscle fiber cross-sectional area, grip strength, myostatin/follistatin mRNA ratio
- Follistatin-344 demonstrates dose-dependent increases in muscle mass (20–35% above baseline in 4-week protocols), but systemic delivery risks off-target activin inhibition affecting reproductive and hepatic function.
- Muscular dystrophy (DMD models)
- mdx mouse AAV vector delivery
- AAV 1×10^12 genome copies IV or IM
- Serum CK levels, dystrophin-positive fiber count, muscle histopathology score
- Gene therapy approaches show 40–60% reduction in fibrotic infiltration and improved force generation, but immune response to AAV capsid remains a translational barrier.
- Liver fibrosis and NASH
- CCl4-induced fibrosis in rodents
- 0.5–2.0 mg/kg IP or IV weekly
- Hepatic collagen content (hydroxyproline assay), stellate cell activation markers (α-SMA), ALT/AST levels
- Follistatin-344 reduces fibrotic progression by 30–50% in prevention models; therapeutic reversal of established fibrosis requires sustained high-dose administration and shows more modest benefit (15–25% reduction).
- Cardiac remodeling post-MI
- LAD ligation in rats or mice
- AAV 5×10^11 genome copies intramyocardial
- Ejection fraction (echo), infarct size (TTC staining), BNP levels
- Follistatin-344 gene therapy preserves ejection fraction by 10–15 percentage points vs control and reduces adverse remodeling, but timing of intervention (≤48 hours post-MI) is critical.
- Ovarian function and PCOS models
- DHEA-induced PCOS in mice
- 10–50 µg IP every 48 hours
- Estrous cycle regularity, ovarian follicle count, serum testosterone and LH levels
- Follistatin reduces activin-driven androgen excess and restores cyclicity in 60–70% of treated animals, suggesting activin inhibition as a mechanistic pathway in PCOS pathophysiology.
- Metabolic regulation and insulin sensitivity
- Diet-induced obesity (DIO) mice
- 1–5 mg/kg SC twice weekly
- Glucose tolerance (GTT/ITT), skeletal muscle GLUT4 expression, adipose tissue inflammation markers
- Follistatin-344 improves insulin sensitivity independent of weight loss, likely through enhanced muscle glucose uptake and reduced adipose tissue macrophage infiltration; effect size: 20–30% improvement in glucose AUC.
- The diversity of research applications reflects follistatin's pleiotropic biological roles. It's not a single-target compound. That breadth creates opportunity for mechanistic discovery but also complicates dose optimization. A dose effective for muscle hypertrophy may be subtherapeutic for fibrosis and supratherapeutic for reproductive endpoints. Experimental design must account for tissue-specific expression of activin, myostatin, and BMPs, as well as receptor density and downstream signaling pathway activation states in each model.